Latest News
July 7, 2016
Integrated Device Technology Inc. announced today that an implantable long-term glucose sensor using IDT’s sensing technology has received government approval to be marketed in European Union (EU) member countries. Maryland-based Senseonics received the CE Mark approval for its Eversense Continuous Glucose Monitoring (CGM) System, featuring an implanted glucose sensor that lasts up to 90 days.
The IDT sensing solution incorporates an LED driver, temperature sensor, photodiodes and other components in a compact package to drive glucose measurements, which are wirelessly communicated to an on-body wearable transmitter.
In developing the semiconductor for Senseonics, IDT engineers selected a technology usually used for hearing aids that can be operated at a voltage as low as 0.85 V.
“Senseonics’ use of our novel technology to develop its Eversense CGM system is a great example of how miniaturized advanced electronics are contributing to improvements in medical care,” said Uwe Guenther, director of mobile sensing at IDT. “The IDT technology used provides an unparalleled level of system integration to deliver the requisite quality and reliability—all in one implantable single-chip solution.”
For more information, visit IDT.
Sources: Press materials received from the company and additional information gleaned from the company’s website.
Subscribe to our FREE magazine,
FREE email newsletters or both!Latest News
About the Author
DE EditorsDE’s editors contribute news and new product announcements to Digital Engineering.
Press releases may be sent to them via [email protected].